This figure visualizes possible shuffling of unrelated donor selection criteria by posttransplant cyclophosphamide (PTCy)–based GVHD prophylaxis. The current evidence is not yet robust enough for PTCy-specific recommendations. CMV, cytomegalovirus; DSA, donor-specific antibodies.